Blog
Blog
AI-driven Advancements in Life Sciences
The momentum behind AI-driven advancements in life sciences has never been stronger, and this trend was spotlighted in Everest Group’s new 2025 PEAK Matrix® report, “Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025.” Trinity Life Sciences is honored to be recognized as a Leader in this comprehensive assessment, a distinction rooted…

Filter posts by:
Blog
Are Current Reimbursement Options for Opioid Use Disorder DTx Causing a Barrier to Widespread Adoption in the USA?
In 2020, Trinity assessed three applications developed to treat Opioid Use Disorders (OUD) (e.g., reSET-O, Connections, DynamiCare) through the lens of ICER conducting a cost-effectiveness evaluation. Only a year later, several more health tech startups have adopted a preventative outlook and seek...

Blog
Insulin Approval Pathways USA vs. EU
Executive Summary Trinity’s Take: All types of insulin products included in this analysis had significantly higher list prices in the USA vs. DEU, GBR, and FRA despite the availability of often equivalent products, brands, and technologies. While the only biosimilar...
Blog
Cell and Gene Therapy Landscape: Challenges and Opportunities for Biotech and Investors
Executive Summary The American Society of Cell & Gene Therapy (ASCGT) wrapped up their 2021 conference earlier this year, which covered a range of topics, from new scientific advances to the evolving pricing and market access dynamics surrounding cell and gene...

Blog
Assessing the Value of Non-Curative Cell and Gene Therapies
Executive Summary Trinity’s Take: Manufacturers should prioritize refining and tailoring their value messaging to communicate the incremental value that their therapy provides over current treatments, optimize their pricing strategy based on the cost-offsets their product generates, and pursue contracting strategies to maximize...

Blog
The 2021 German Federal Election: What is the Future Outlook for Healthcare in Germany?
Written by Caspar Kengeter and Manon Ricard

Blog
AI-Based Software Paige Prostate is Granted FDA Approval Through the De Novo Regulatory Pathway
Paige Prostate is the first artificial intelligence (AI)-based software designed to identify areas of concern (i.e., high likelihood of containing cancer) on a prostate biopsy image so they can be flagged for further review by a pathologist. The program is...
